Work Here?
Overview
Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.
About Noctrix Health
Industries
Healthcare
Company Size
51-200
Company Stage
Acquired
Total Funding
$450.5M
Headquarters
Pleasanton, California
Founded
2018
People at Noctrix Health
People at Noctrix Health who can refer or advise you
Simplify's Take
What believers are saying
- ResMed's $340M acquisition integrates Nidra into its sleep health portfolio, leveraging existing sleep physician and HME channels for rapid scaling.
- Noctrix's $24M annual run rate revenue grows faster than ResMed's core business, signaling strong post-acquisition financial performance.
- Angelini Ventures achieves its first portfolio exit via this deal, validating Noctrix's clinical efficacy and commercial potential in wearable therapeutics.
What critics are saying
- ResMed prioritizes its $340M sleep apnea business over Noctrix's $24M run-rate, risking reduced NTX100 R&D and supply chain margin erosion.
- Only 12% of US sleep physicians prescribe neuromodulation devices due to absent Medicare coverage for Nidra, blocking commercial adoption despite FDA clearance.
- Philips launched a similar peroneal stimulator at $299, undercutting Nidra's $450 price and threatening 20–30% market share loss within 12–18 months.
What makes Noctrix Health unique
- Noctrix offers FDA De Novo-classified Nidra TOMAC therapy for drug-refractory RLS, a non-pharmacologic wearable neuromodulation device.
- Its TOMAC system delivers sustained peroneal nerve stimulation to suppress RLS symptoms while enabling sleep-compatible low-level muscle activation.
- Noctrix targets the 7% global adult population with moderate-to-severe RLS, addressing a major unmet need in sleep neurology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$450.5M
Above
Industry Average
Funded Over
5 Rounds
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -3%Noctrix Health, Inc. announced that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation, with strong support from insiders, including OrbiMed and Treo Ventures.
Noctrix Health is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Noctrix Health
Industries
Healthcare
Company Size
51-200
Company Stage
Acquired
Total Funding
$450.5M
Headquarters
Pleasanton, California
Founded
2018
Noctrix Health is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today